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REVIEW
Abstract: Insulin glargine is an analogue of human insulin that is modified to provide a
consistent level of plasma insulin over a long duration. Pharmacokinetic and pharmacodynamic
studies show that a single injection of insulin glargine leads to a smooth 24-hour time–action
profile with no undesirable pronounced peaks of activity. In clinical trials, this profile has
been associated with at least equivalent, if not better, glycemic control than other traditional
basal insulins and a significantly lower rate of overall and nocturnal hypoglycemia. The
convenience of a once-daily injection, a lack of need for resuspension (insulin glargine is a
clear solution when injected), and lower rates of hypoglycemia should translate into
improvements in patient treatment satisfaction. This review appraises the evidence for the
view that insulin glargine represents an advance in basal insulin therapy for both type 1 and
type 2 diabetes patients.
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Introduction
While insulin remains the only antihyperglycemic therapy for type 1 diabetes, oral
agents have been the mainstay of therapy for those with type 2 diabetes. Oral therapies
are limited in their ability to maintain tight glycemic control in the long term (UKPDS
1995a, 1995b). There is increasing support for the earlier initiation of insulin in
patients with type 2 diabetes to ensure tight glycemic control through the period of
progressive β-cell failure and secondary failure of oral antidiabetes agents (Campbell
and White 2002; Home et al 2003).
Since the first use of insulin over 80 years ago, a major aim of research has been
the ever closer imitation of physiological insulin delivery. Basal insulin secretion is
essential for the maintenance of fasting glucose levels, especially through inhibition
of excessive glucose output from the liver. Advances in purification methods and
genetic engineering have provided a range of short-, intermediate-, and long-acting
insulin formulations (Feher and Bailey 2004). Insulin glargine was the first long-
acting insulin analogue to become available and appears to provide a more
physiological and convenient method of basal insulin replacement than older long-
acting insulin formulations.
Tight glycemic control – an essential aim
Two landmark studies, UK Prospective Diabetes Study (UKPDS) in type 2 diabetes
(UKPDS 1998a) and the Diabetes Control and Complications Trial (DCCT) in type 1
diabetes (DCCT 1993), definitively proved the benefits of tight glycemic control in
reducing the risk of microvascular complications and suggested possible benefits for
cardiovascular disease (CVD) outcomes in people with diabetes.
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Microvascular complications
In the DCCT, 1441 patients with type 1 diabetes were
randomized to receive intensive therapy (administered either
with an external insulin pump or at least three daily insulin
injections) or conventional therapy (one or two insulin
injections per day) (DCCT 1993). After 3 months, and for
the remainder of the 6.5-year study, the mean glycosylated
hemaglobin (HbA1c) was significantly lower in the intensive
group than in the conventional group (p < 0.001). The
intensive group maintained a mean HbA1c of approximately
7.2% versus approximately 9.0% in the conventional group.
This improvement in glycemic control reduced the risk of
developing retinopathy by 76% (95% confidence interval
[CI]; 67%–82%), of development of clinical neuropathy by
60% (95% CI; 38%–74%), and of microalbuminuria and
albuminuria by 39% (95% CI; 21%–52%) and 54% (95%
CI; 19%–74%), respectively (DCCT 1993). Furthermore,
an observational follow-up of the original DCCT cohort,
known as the Epidemiology of Diabetes Interventions and
Complications (EDIC) study, reported maintenance of these
benefits after a further 4 years (DCCT/EDIC 2000).
Similarly, in the UKPDS, 5102 patients with type 2
diabetes were randomized to receive either conventional
dietary treatment or intensive blood glucose control using
either insulin or a sulfonylurea (UKPDS 1998a). Over the
10-year study period, the mean HbA1c in the intensive group
was reduced by 11% compared with those on conventional
therapy (mean HbA1c of 7.9% [95% CI; 6.2%–8.2%] versus
7.0% [95% CI; 6.9%–8.8%] for conventional versus
intensive therapy) This reduction in HbA1c was associated
with a 25% reduction in the risk of microvascular
complications (p = 0.0099) (UKPDS 1998a).
Cardiovascular disease
Results from the EDIC study, the long-term follow up of
the DCCT, suggest a cardiovascular (CV) benefit of tight
glycemic control in type 1 diabetes (Nathan et al 2003).
Patients assigned to intensive (n = 618) or conventional
(n = 611) therapy received ultrasound scans of the internal
and common carotid arteries at year 1 and year 6 of the
study. Progression of intima media thickness (IMT), a well-
established marker of atherosclerosis, was significantly less
in those assigned to intensive versus conventional therapy
(p = 0.01 and p = 0.02 for internal and common carotid IMT,
respectively). These studies suggest that tight glycemic
control could reduce the risk of CV events, at least in part,
through modifying the atherosclerotic disease process.
Results from the DCCT/EDIC study published in December
2005 showed that of the 1375 volunteers continuing to
participate in the DCCT/EDIC, the intensively treated
patients had approximately half the number of CV events
compared with those treated conventionally (Nathan et al
2005).
In the UKPDS, the improved glycemic control in the
intensive group was associated with a 16% reduction in the
risk of myocardial infarction (MI), although the result did
not quite reach accepted statistical significance (p = 0.052)
(UKPDS 1998a). In a sub-study of the UKPDS, 753 obese
patients with type 2 diabetes were randomized to intensive
therapy with metformin or conventional therapy. After a
median follow-up of 10.7 years, metformin was associated
with a 39% reduction in the risk of MI (p = 0.01). A 96%
(p = 0.039) increase in diabetes-related death in a small
subset of patients treated with metformin plus sulfonylurea,
however, makes the interpretation of these results difficult
(UKPDS 1998b).
Limitations of current insulin
regimens
Advances in genetic engineering, formulation science, and
medical device technology have brought the aim of tight
glycemic control ever closer (Feher and Bailey 2004). In
type 1 diabetes, complex regimens involving short-,
intermediate-, or long-acting insulins aim to mimic
physiological insulin delivery. These regimens are far from
perfect, however, as shown by the fact that even in the highly
motivated setting of the DCCT, only 5% of those assigned
to intensive therapy maintained an average HbA1c below
the target level of 6.5% throughout the study (DCCT 1993).
Furthermore, the DCCT highlighted the difficulty in
balancing tight glycemic control and hypoglycemia with
those in the intensive therapy group being at 3-fold greater
risk of severe hypoglycemia (p < 0.001) (DCCT 1993).
In type 2 diabetes, insulin therapy is usually reserved
for those who are failing on oral therapy, but its use is often
delayed in these patients. This is despite the fact that insulin
is the only therapy that can control glycemia in the long
term (UKPDS 1998a; Wright et al 2002). It is well
established that there are practitioner and patient barriers to
the initiation of insulin therapy in type 2 diabetes, such as
perceived complexity, fear of injections, and the fear of
hypoglycemia (Cryer 1999; Wallace and Matthews 2000).
In both type 1 and type 2 diabetes, complexity of
regimen, the need for multiple dosing, and a fear of
hypoglycemia underlie much of the failure to reach targets
for glycemic control. Insulin glargine is an insulin analogueVascular Health and Risk Management 2006:2(1) 61
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that has been available in the US and UK since 2001. This
form of insulin has attributes that may contribute to
overcoming some of the barriers to tight glycemic control.
Limitations of long-acting insulins
The aim of basal insulin replacement is to provide a constant
level of insulin between meals without increasing the risk
of hypoglycemia, particularly at night. Long-acting, basal
insulins are modified to delay their absorption. The most
frequently used basal insulins are insulins complexed with
protamine (neutral protamine Hagedorn [NPH] insulins) or
the hexamer-stabilizing agent zinc (lente and ultralente
insulins) (Feher and Bailey 2004). These formulations fall
short of providing an appropriate basal supply of insulin
because of variable absorption, undesirable peaks in
hypoglycemic action, and an insufficient duration of action.
Basal NPH insulin produces a maximal insulin concentration
4–6 hours after injection, which can cause hypoglycemia
and often necessitates twice-daily injections (Zinman et al
1999). Furthermore, subcutaneous absorption of these
formulations varies considerably and undesirable plasma
concentration peaks can lead to hypoglycemic episodes,
especially during the night (Heinemann and Richter 1993).
Conversely, the same unpredictable absorption can also lead
to high fasting glucose levels in the morning (Gillies et al
2000). Ultralente formulations share many of these
limitations and are also associated with wide inter- and intra-
individual variability in pharmacodynamics and pharmaco-
kinetics (Hirsch 1998, Rosskamp and Park 1999).
A further practical problem that arises with NPH insulin
is the need to mix thoroughly before injection. A study of
109 diabetes patients treated with NPH insulin found that
inadequate suspension was common (only 9% of patients
tipped and rolled their insulin pens more than 10 times)
with a consequent wide variation in the dose of insulin
administered (Jehle et al 2000).
These limitations have led to attempts to develop
improved basal insulins with no pronounced peaks in insulin
levels, reproducible antihyperglycemic efficacy, and once-
daily administration.
Insulin glargine – an improved
basal insulin?
Insulin glargine was developed as an improved long-acting,
basal insulin. It is an analogue of human insulin that is
produced in a non-pathogenic strain of Escherichia coli.
Insulin glargine differs from human insulin by the addition
of two arginine amino acids to the C-terminus of the
B-chain and the replacement of asparagine at position A21
by glycine. These changes shift the isoelectric point so that
the molecule is soluble at an acid pH, but less soluble at
neutral physiological pH levels. This results in a clear
solution (pH 4.0) that when injected forms a precipitate in
the subcutaneous tissue, which delays absorption and
prolongs duration of action (Bahr et al 1997). The absorption
characteristics of insulin glargine are not affected by the
site of injection (arm, leg, or abdominal regions).
Furthermore, compared with NPH insulin, the absorption
rate is significantly slower with approximately 50% of the
injected dose of insulin glargine still detectable after 24
hours compared with approximately 20% of the NPH insulin
dose (Owens et al 2000).
A potential major advantage of insulin glargine over
NPH insulin and ultralente preparations is a lack of
pronounced peaks in plasma insulin concentrations and a
more constant delivery of insulin over a 24 hour period.
This smooth profile was clearly shown in studies of insulin
glargine versus NPH insulin in healthy volunteers (Figure 1)
and of insulin glargine versus NPH and ultralente insulin in
patients with type 1 diabetes (Figure 2) (Heinemann et al
2000; Lepore et al 2000). In fact, in this latter study, the
delayed absorption of insulin glargine provided a consistent
delivery of insulin that closely mimicked insulin delivery
by continuous subcutaneous insulin infusion (CSII)
(Figure 2) (Lepore et al 2000). Furthermore, in this study,
interindividual variability in plasma insulin concentrations
was lower with insulin glargine than with NPH or ultralente
(Lepore et al 2000).
These pharmacokinetic studies highlight the potential
of insulin glargine to be an improved basal insulin for
patients with diabetes.
Insulin glargine – balancing tight
glycemic control and hypoglycemia
Much evidence now supports the suggestion that the
pharmacokinetics and pharmacodynamics of insulin
glargine can translate into effective glycemic control with a
reduced risk of hypoglycemia in patients with type 1 and
type 2 diabetes. While a single dose of insulin glargine will
achieve 24-hour coverage in the large majority of patients,
a minority of patients may experience a premature decline
in activity that typically occurs between 18 and 24 hours.
In these cases, the appropriate insulin glargine dose can be
divided between two doses 12 hours apart. Alternatively,
the decline in activity can be compensated for by the additionVascular Health and Risk Management 2006:2(1) 62
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of 1–2 units of regular insulin mixed with preprandial fast
acting insulin before dinner. This ‘pseudo-basal’ dose will
maintain insulinization, but eliminate the need to split the
insulin glargine dose and increase the number of injections
(Bohannon 2003).
An appraisal from the UK National Institute of Clinical
Excellence (NICE) has recommended insulin glargine as a
treatment option for all type 1 diabetes patients and for
patients with type 2 diabetes who require assistance from a
carer or healthcare professional to administer insulin, whose
life is restricted by recurrent episodes of symptomatic
hypoglycemia and for those who would otherwise need
twice-daily basal insulin injections in combination with oral
antidiabetic drugs (NICE 2002).
Type 1 diabetes
The first indications that insulin glargine could offer
improved glycemic control came in two short-term trials.
Rosenstock et al (2000) assigned 256 patients with type 1
diabetes to receive insulin glargine or NPH insulin. Insulin
glargine produced more stable fasting plasma glucose (FPG)
 
Figure 1 Serum insulin profiles for insulin glargine and NPH insulin in healthy volunteers.
Mean serum insulin concentrations ± SEM after subcutaneous injections of 0.4 U/kg body weight of insulin glargine and NPH insulin on three different study days in 15
healthy volunteers, corrected for serum insulin concentrations seen with placebo. Reproduced from Heinemann et al 2000. Copyright © American Diabetes
Association. From Diabetes Care, 23:644–9. Reprinted with permission from The American Diabetes Association.
Abbreviations: NPH, neutral protamine Hagedorn; SEM, standard error of the mean.
Figure 2 Serum insulin profiles for four different basal insulins in patients with
type 1 diabetes.
Free plasma insulin concentrations after subcutaneous injection of insulin
glargine, NPH insulin, Ultralente and continuous subcutaneous infusion of insulin
lispro. Reproduced from Lepore et al 2000. Copyright © 2000 American Diabetes
Association. From Diabetes, 49:2142–8. Reprinted with permission from The
American Diabetes Association.
Abbreviations: NPH, neutral protamine Hagedorn.Vascular Health and Risk Management 2006:2(1) 63
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levels and reduced mean FPG levels by 2.2 mmol/L
compared with patients taking NPH insulin (p = 0.0001).
The advantage of insulin glargine over NPH insulin was
seen mostly in patients who had previously been on NPH
insulin once-daily. In this short study, the rates of
hypoglycemia were higher in the insulin glargine group than
those taking NPH (p = 0.03), although the authors state that
the difference was not clinically meaningful. In a further
study of similar design in 333 patients, insulin glargine
produced significantly lower FPG (–1.88 mmol/L,
p = 0.0005), fasting self-monitored blood glucose levels
(–0.80 mmol/L, p = 0.002), and HbA1c levels (–0.14%,
p = 0.03) versus NPH insulin (Pieber et al 2000). Although
the overall frequency of hypoglycemia was similar in both
treatment groups, nocturnal hypoglycemia over the
treatment period as a whole was significantly lower among
patients treated with insulin glargine than in patients treated
with once daily NPH (36% versus 55%, p = 0.0037) although
an analysis of rates of nocturnal hypoglycemia for the final
week of the trial did not show any significant differences
(Pieber et al 2000).
A longer-term study of 16 weeks (n = 310) also showed
significant improvements in FPG levels (1.63 mmol/L versus
0.66 mmol/L, p = 0.0001) and more consistent FPG levels
with insulin glargine compared with NPH insulin (median
decrease in variability at study end of 3.44 mmol/L versus
0.79 mmol/L, p = 0.0124). Furthermore, a greater proportion
of patients in the insulin glargine group reached a target
fasting glucose level of 6.6 mmol/L than in the NPH insulin
group (29.6% versus 16.8%, p value not reported) (Raskin
et al 2000).
While similar rates of hypoglycemia were observed in
the 16-week study, a 28-week trial of 534 patients found
that compared with NPH insulin, insulin glargine was
associated with a lower rate of symptomatic hypoglycemia
(39% versus 49%, p = 0.0219) and nocturnal hypoglycemia
(18.2% versus 27%, p = 0.0116) (Ratner et al 2000). As with
the shorter-term trial, insulin glargine  was  more  effective
at  reducing  FPG  levels (–1.76 mmol/L versus –0.33 mmol/L
for insulin glargine and NPH insulin, respectively,
p = 0.0145) (Ratner et al 2000). Consistent results were
reported from another 28-week trial of 394 patients (Hershon
and Blevins 2004). In this case, insulin glargine was
compared with a twice-daily NPH insulin basal regimen.
FPG levels were reduced by –1.17 mmol/L versus
–0.56 mmol/L in the insulin glargine and NPH insulin
groups, respectively (p = 0.015), and a greater percentage
of patients treated with insulin glargine reached the target
FPG (32.6% versus 21.3%; p = 0.015). As with the earlier
trial, significantly fewer symptomatic hypoglycemic events
occurred with insulin glargine than with NPH insulin (36.6%
versus 46.2%; p = 0.033).
One study has compared insulin glargine with ultralente
insulin and the results were consistent with those found for
comparisons with NPH formulations. Although the ability
to assess clinical significance is limited by its small size,
this randomized, cross-over trial (n = 22) found that in
addition to providing more stable nocturnal glucose control
(continuous subcutaneous glucose monitoring [CSGM],
nocturnal values: 49.06 ± 4.74 versus 62.36 ± 5.21,
p = 0.036), being more effective at lowering FPG levels
(between group difference –35.70 ± 15.97, p = 0.047) and
lowering the number of hypoglycemic episodes (between
group difference for day and night episodes of symptoms
suggestive of hypoglycemia and simultaneous capillary
blood glucose < 3.3 mmol/L: –1.5, p = 0.002 and –3.0,
p = 0.0015, respectively), insulin glargine significantly
reduced HbA1c levels compared with ultralente insulin
(6.82% versus 7.02%, p = 0.03) (Kudva et al 2005).
Insulin glargine was found to provide at least equivalent
glycemic control as NPH insulin in children and adolescents
with type 1 diabetes. This 6-month trial randomized 349
patients aged 5–16 years to receive insulin glargine once-
daily at bedtime or NPH insulin either once- (at bedtime in
114 patients) or twice-daily (in the morning and at bedtime
in 61 patients). Changes in HbA1c from baseline to endpoint
were similar in the insulin glargine and NPH insulin groups
(–0.28 ± 0.09% and –0.27 ± 0.09%, respectively), but the
corresponding changes in FPG decreased more in the insulin
glargine than NPH insulin groups (–1.29 mmol/L versus
–0.68 mmol/L, p = 0.02). Overall rates of hypoglycemia were
similar in both groups (78.9% and 79.3% for insulin glargine
and NPH insulin, respectively) (Schober et al 2001).
Type 2 diabetes
The efficacy of insulin glargine has also been demonstrated
in patients with type 2 diabetes with inadequate glycemic
control on oral antidiabetic agents. Two trials compared
NPH insulin with insulin glargine added to existing oral
agents.
Riddle et al (2003) compared the addition of either
insulin glargine or NPH insulin with existing regimens of
one or two oral antidiabetic agents. This 24-week,
randomized trial enrolled 756 patients. Although both basalVascular Health and Risk Management 2006:2(1) 64
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insulins reduced FPG and HbA1c levels by similar amounts
(FPG: 6.4 mmol/L versus 6.6 mmol/L; HbA1c: 6.96% versus
6.97% for insulin glargine and NPH insulin, respectively),
25% more patients attained a target HbA1c level of = 7%
without experiencing nocturnal hypoglycemia with insulin
glargine than with NPH insulin (p < 0.05) (Riddle et al 2003).
The overall rate of hypoglycemia, rate of symptomatic
events, and rate of confirmed events in the insulin glargine
group were reduced by 21%, 29%, and 41%, respectively
(Riddle et al 2003). Yki-Jarvinen’s group designed a similar
trial, but the treatment period was one year. Again, insulin
glargine and NPH insulin reduced HbA1c levels by a similar
amount, but there was less nocturnal hypoglycemia (9.9%
versus 24.0% of patients, p < 0.001) and insulin glargine
was associated with better post-meal glucose control than
NPH insulin (9.9 mmol/L versus 10.7 mmol/L, p < 0.002)
(Yki-Jarvinen et al 2000).
Optimizing treatment algorithms
As insulin glargine is still a relatively new form of therapy,
the definition of the optimal initiation and maintenance
regimen is ongoing. Recently published data from the
AT.LANTUS (A Trial comparing Lantus
® Algorithms to
achieve Normal blood glucose Targets in patients with
Uncontrolled blood Sugar) study suggest that a greater
degree of self-management can improve glycemic control.
The study compared two algorithms for the initiation of
therapy with insulin glargine in 4961 patients with type 2
diabetes (Davies et al 2005). Patients were randomized to a
physician-managed algorithm, where insulin doses were
titrated at each physician visit, or to a self-management
algorithm where patients adjusted their own dose every 3
days. After 24 weeks, HbA1c levels were lowered
significantly more in the self- versus physician-managed
algorithm (–1.22% versus –1.08% mmol/L, p < 0.001), as
were FPG levels (–3.4% versus 3.1% mmol/L, p < 0.001).
Importantly, this improvement in glycemic control was
achieved without an increase in the incidence of severe
hypoglycemia (Davies et al 2005).
Safety profile of insulin glargine
Various definitions and methods have been used to measure
hypoglycemia in trials of insulin glargine, which limits the
ability to generalize the findings across all patients with
diabetes. While some studies have shown similar rates of
hypoglycemia when compared with NPH insulin, there is
also evidence insulin glargine can maintain effective glucose
control and reduce the risk of hypoglycemia. Rosenstock et
al (2001) randomized 518 patients with type 2 diabetes, who
were already being treated with basal NPH insulin and
regular insulin, to receive either insulin glargine or NPH
insulin once- or twice daily. While improvements in HbA1c
were comparable, the group who switched to insulin glargine
showed a 25% decrease in the rate of nocturnal hypo-
glycemia (26.5% versus 35.5%, p = 0.0136). A recent meta-
analysis of four open-label, randomized trials of insulin
glargine versus NPH insulin adds further weight to this
assertion. In total, 2304 patients were randomized and while
glycemic control was similar between groups, there was a
significant and consistent reduction in the risk of
hypoglycemia (Table 1) (Rosenstock et al 2005).
The overall safety profile of insulin glargine is similar
in patients with type 1 or type 2 diabetes. Insulin glargine is
generally well tolerated and appears to have a very similar
safety profile to NPH insulin, the most relevant comparator.
The only difference is a greater frequency of injection-site
pain with insulin glargine reported in some, but not all, trials
(Raskin et al 2000; Ratner et al 2000; Rosenstock et al 2001).
This increase in pain may be related to the product’s acid
pH, but this rarely leads to discontinuation.
Weight gain has long been an issue with insulin therapy.
Insulin glargine has been associated with a mean weight
gain of up to 2.02 kg in a 39-month study of 239 patients
being treated in combination with oral antidiabetes agents,
but many studies have reported no significant weight gain
despite significant improvements in HbA1c (Dunn et al
2003). Some evidence suggests that insulin glargine may
be associated with less weight gain than NPH insulin. In
three studies, NPH insulin was associated with significantly
more weight gain than insulin glargine (Raskin et al 2000;
Rosenstock et al 2001; Garg et al 2004). In one 16-week
trial in type 1 diabetes, weight gain was greater with NPH
insulin than with insulin glargine (–0.12 kg with insulin
glargine versus 0.54 kg with NPH insulin, p = 0.034) (Raskin
et al 2000) In a further study of 196 patients with type 1
diabetes, mean weight gain from baseline was significantly
higher with NPH insulin (1.4 kg ± 1.8 kg, p = 0.004)
compared with insulin glargine (no significant weight gain,
p = 0.4). In a 16-week trial in patients with type 2 diabetes,
weight gain was 0.4 kg with insulin glargine versus 1.4 kg
with NPH insulin (p < 0.0007) (Rosenstock et al 2001). In
contrast, one study reported similar gains in mean body
weight following 1 year of treatment of patients with type 2
diabetes with insulin glargine (+2.6 kg, n = 214) and NPH
insulin (+2.3 kg, n = 208) (Yki-Jarvinen et al 2000).Vascular Health and Risk Management 2006:2(1) 65
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Insulin glargine has up to 6-fold greater potency at the
insulin-like growth factor-1 (IGF-1) receptor than regular
human insulin and this has raised the concern of mitogenic
effects in cells that express a high number of IGF-1 receptors
(Kurtzhals et al 2000). IGF-1 has also been implicated in
the progression of retinopathy. Reports that insulin glargine
was associated with an increase in three-step progression
of retinopathy in the Early Treatment Diabetic Retinopathy
study were refuted when an independent panel convened
by Aventis reviewed the data (Bolli and Owens 2000).
Treatment of rats and mice for up to 2 years at doses up
to 10-times the normal starting dose of insulin glargine have
not suggested an increase in carcinogenicity (Bolli and
Owens 2000; Lantus 2004). The mitogenic activity of insulin
glargine was not increased compared with regular human
insulin in in vitro tests using cell lines that mainly express
insulin receptors (Berti et al 1998). Furthermore, the uptake
of thymidine into DNA in human cultured skeletal muscle
cells from patients with type 2 diabetes was equivalently
stimulated by regular human and insulin glargine, but was
significantly more potently stimulated by IGF-1 (EC50s:
51 ± 14 nM, 63 ± 18 nM and 0.57 ± 0.20 nM, respectively)
(Ciaraldi et al 2001).
While there is no evidence that insulin glargine is
carcinogenic in routine clinical use, the theoretical risk of
increased mitogenesis reinforces the need for appropriate
pharmacovigilance.
The concerns on mitogenesis mean insulin glargine is
not recommended for use during pregnancy, despite the fact
this treatment may enhance the ability to reach the tight
glycemic control recommended for diabetic pregnancies.
Di Cianni et al (2005) reported the use of insulin glargine
in five women with unplanned pregnancy from the pre-
conception period to 6–12 weeks post-conception, when
they were switched to NPH insulin or CSII. Insulin glargine
did not seem to affect embryo–fetal development during
this critical period of embryogenesis as all deliveries were
viable, had no minor or major congenital malformations, or
any complications during the post-partum period. This
evidence adds to the small number of reported case studies
where the use of insulin glargine did not affect embryo-
genesis in pregnant women with diabetes (Devlin et al 2002;
Holstein et al 2003).
Case reports of nausea and vomiting in patients receiving
insulin glargine have been published, although this adverse
event appears to be rare (Dixon and Bain 2005).
Insulin glargine – patient
satisfaction
The clinical benefits of insulin glargine over traditional basal
insulins have been demonstrated in clinical trials. Combined
with the convenience of once-daily injection and the absence
of suspension problems, this agent may help to take a step
closer to achieving tight glycemic control in many patients
with diabetes. Do these changes lead to an improvement in
treatment satisfaction? A prospective audit of the
introduction of insulin glargine in 83 type 1 diabetes patients
transferred from NPH insulin found that the switch reduced
morning blood glucose and HbA1c levels and improved
patient satisfaction and subjective well-being (Gallen and
Carter 2003). This appears to confirm another study that
showed insulin glargine was associated with consistent and
significant improvements in treatment satisfaction, as
measured by the Diabetes Treatment Satisfaction
Questionnaire (Witthaus et al 2001). The study gathered
questionnaires from 517 patients with type 1 diabetes
enrolled in a 28-week randomized, controlled clinical trial
of insulin glargine versus NPH insulin. While general well
being was not significantly different between groups at any
point during the trial, treatment satisfaction improved over
the trial period with insulin glargine and slightly deteriorated
Table 1 Meta-analysis of episodes of hypoglycemia with insulin glargine versus NPH insulin
(Derived from Table 3 of Rosenstock et al 2005)
Insulin glargine
Type of documented Insulin glargine NPH insulin significant % risk
symptomatic hypoglycemia (% of patients) (% of patients) p reduction
Overall 54.2 61.2 0.0006 11
Nocturnal 28.4 38.2 < 0.0001 26
Non-nocturnal 49.6 51.7 0.2553 –
Severe 1.4 2.6 0.0422 46
Severe nocturnal 0.7 1.7 0.0231 59
Severe non-nocturnal 0.8 0.9 0.7296 –
Abbreviations: NPH, neutral protamine Hagedorn.Vascular Health and Risk Management 2006:2(1) 66
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in the NPH insulin group (p = 0.0001). Furthermore, scores
relating to perceived frequency of hyperglycemia and
hypoglycemia were significantly better for insulin glargine
and NPH insulin (Witthaus et al 2001). One weakness of
this trial is the open-label design, which might have allowed
the bias of the subjective measures being tested through
knowledge of the treatment being allocated.
Emerging uses of insulin glargine
The long duration of action and lack of peak activity has
raised the possibility of insulin glargine being useful in a
number of special clinical settings. Frail elderly patients with
diabetes, in whom hypoglycemia is a particular risk, may
benefit from a reduced number of injections and from a
reduced risk of hypoglycemia. As insulin glargine is a clear
solution, concerns of adequate mixing of isophane insulins
are alleviated for those with problems with dexterity.
Furthermore, for those who cannot self-inject, the once-a-
day regimen can facilitate the administration of insulin
glargine at a time convenient for a community nurse.
Insulin glargine may also be useful in those who require
continuous enteric tube feeding as the peakless nature and
long duration of action may circumvent the need for
continuous intravenous or subcutaneous insulin infusion.
In fact, a case study reported by Putz and Kabadi (2002)
outlines the successful use of insulin glargine in a 60-year
old man who required enteral tube feeding following
radiotherapy for squamous cell carcinoma.
Conclusion
Managing diabetes with insulin is primarily based on the
balance between the necessity of tight glycemic control and
the risks associated with hypoglycemia. Insulin glargine
appears to improve this balance such that at least equivalent
glycemic control can be achieved with a lower risk of
hypoglycemia than traditional basal insulins. In patients with
type 2 diabetes, the reduced risk of hypoglycemia with
insulin glargine, combined with the flexibility of once-daily
dosing at any time of the day, is likely to make insulin a
more acceptable option, which may mean that patients are
more open to start insulin earlier and to intensify their insulin
sooner. In the long-term this may lead to improvements in
HbA1c and thereby a reduction in the long-term
complications of diabetes. In type 1 diabetes the reduced
risk of hypoglycemia with insulin glargine, combined with
improved treatment satisfaction, means that patients should
be able to intensify their treatment and improve their ability
to reach HbA1c targets, which, in the long term, may also
lead to a reduced risk of complications. These hypotheses
need to be tested with long-term comparator studies of
insulin glargine and other insulins.
Disclosure
Professor Barnett has provided advice and given lectures
for remuneration and has received research grants from all
the major companies involved in producing insulin and oral
diabetic medication.
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